Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Her2-negative Metastatic Breast Cancer”

753 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 753 results

Testing effectiveness (Phase 2)Looking for participantsNCT06176261
What this trial is testing

DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

Who this might be right for
Breast CancerBreast Cancer FemaleMetastatic Triple-Negative Breast Carcinoma+4 more
Nancy Lin, MD 58
Testing effectiveness (Phase 2)Study completedNCT02536742
What this trial is testing

Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
ETOP IBCSG Partners Foundation 124
Large-scale testing (Phase 3)Active Not RecruitingNCT05654623
What this trial is testing

Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

Who this might be right for
Advanced Breast Cancer
Pfizer 624
Testing effectiveness (Phase 2)Study completedNCT03213041
What this trial is testing

Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor NegativeEstrogen Receptor PositiveHER2/Neu Negative+4 more
Northwestern University 12
Testing effectiveness (Phase 2)Ended earlyNCT06851442
What this trial is testing

Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Who this might be right for
Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 8
Large-scale testing (Phase 3)Looking for participantsNCT07062965
What this trial is testing

Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Who this might be right for
Breast Cancer
Pfizer 400
Testing effectiveness (Phase 2)Ended earlyNCT01531764
What this trial is testing

BIBW 2992 (Afatinib) and Vinorelbine

Who this might be right for
Carcinoma Breast Stage IV
University of Magdeburg 2
Testing effectiveness (Phase 2)Looking for participantsNCT04573231
What this trial is testing

Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer

Who this might be right for
Breast CancerHER2-negative Breast CancerMetastatic Breast Cancer
University of Wisconsin, Madison 13
Testing effectiveness (Phase 2)UnknownNCT03204734
What this trial is testing

Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Zhejiang Cancer Hospital 132
Testing effectiveness (Phase 2)Study completedNCT02723877
What this trial is testing

PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)

Who this might be right for
Metastatic Breast Cancer
PIQUR Therapeutics AG 41
Testing effectiveness (Phase 2)Ended earlyNCT01207102
What this trial is testing

Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Duke University 10
Large-scale testing (Phase 3)Looking for participantsNCT07060807
What this trial is testing

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Who this might be right for
Breast Neoplasms
Merck Sharp & Dohme LLC 1,000
Testing effectiveness (Phase 2)Study completedNCT00951054
What this trial is testing

NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Nippon Kayaku Co., Ltd. 61
Very early researchNot Yet RecruitingNCT07671092
What this trial is testing

Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC

Who this might be right for
Metastatic Urothelial CarcinomaBreast CancerTNBC - Triple-Negative Breast Cancer+2 more
RayzeBio, Inc. 40
Large-scale testing (Phase 3)Study completedNCT01131195
What this trial is testing

Metronomic Therapy in Metastatic Breast Cancer.

Who this might be right for
Breast Cancer
Swiss Cancer Institute 139
Testing effectiveness (Phase 2)Study completedNCT02260531
What this trial is testing

Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases

Who this might be right for
Breast CancerBrain Tumor - Metastatic
Dana-Farber Cancer Institute 36
Large-scale testing (Phase 3)Active Not RecruitingNCT07371910
What this trial is testing

Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer

Who this might be right for
Metastatic Breast CancerHRD-Positive/HER2-Negative Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 200
Testing effectiveness (Phase 2)Ended earlyNCT03952325
What this trial is testing

Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC

Who this might be right for
Breast Cancer
Odonate Therapeutics, Inc. 294
Early research (Phase 1)Looking for participantsNCT05461768
What this trial is testing

BL-M07D1 in Patients With Locally Advanced or Metastatic HER2-Positive/Negative Breast Cancer and Other Solid Tumors

Who this might be right for
Breast CancerLocally Advanced or Metastatic Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd. 348
Not applicableStudy completedNCT02613208
What this trial is testing

Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Participants With HER 2-Negative Aggressive Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 111
Next Page